HULSPHARMA
ActiveSummary
HULSPHARMA has been active since 1988 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €889,981 and a net result of €133,452. Equity remains stable across the filed financial years (±2.3% per year). Its solvency ranks better than 85% of 5,007 sector peers (NACE 47, financial year 2025). The computed 12-month bankruptcy probability is below 0.1% (very low).
History
Acts, filings and financial milestones
22-12
Gazette deed
Resignations: SERCAM (director) and CAMS Carolus (director)Reappointment: SERCAM (enige niet statutaire bestuurder) · Permanent representative: CAMS Inge · Amendment of the articles11 facts ▸
- General meeting, 18-12-2023
- Amendment of the articles (2 times)
- Power of attorney, Lien Van Cauwenbergh
- Director resignation, SERCAM (director)
- Director resignation, CAMS Carolus (director)
- Director reappointment, SERCAM (enige niet statutaire bestuurder)
- Director discharge, SERCAM
- Director discharge, CAMS Carolus
- Registered office clause, “2235 Hulshout, Grote Baan 146, Vijfde besluit” (deed in Dutch)
- Permanent representative, CAMS Inge
- Power of attorney, CAMS Inge
About the unread acts
Of the 4 Belgian Official Gazette deeds we know for this company, 1 has been read. The other 3 have not been read yet: what they contain is neither established nor disproved here.